For decades, Africa has carried the heaviest burden of sickle cell disease and the lightest share of its treatment. The continent accounts for the overwhelming majority of the world's cases, yet for generations, the medicine that actually works, hydroxyurea has had to travel here from factories in Europe and North America, arriving late, priced high, and often not at all. That imbalance just cracked.

Africa accounts for nearly 80 per cent of cases of the inherited red blood cell disorder but has relied on expensive imported medication.

For the first time in Africa, a Senegalese laboratory is producing generic hydroxyurea, the gold standard in sickle cell treatment with the hopes of providing cheaper treatment…